Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
Prof. Susan Treves and Prof. Francesco Zorzato, University Hospital Basel
Abstract (Lay summary see below)
Both dominantly and recessively inherited RYR1 mutations have been identified in patients with congenital myopathies and are often associated with different phenotypes. Dominant RYR1 mutations are the underlying cause of malignant hyperthermia/rhabdomyolysis/ exertional heat intolerance and central core disease. Recessive mutations are found in more severely affected patients presenting with multi-minicore disease and centronuclear myopathy. From a functional point of view dominant mutations affect the biophysical properties of the ryanodine receptor 1 (RyR1) calcium channel, whereas recessive mutations don’t, though their presence is accompanied by a significant reduction in the content of RyR1 protein in patients’ muscles. Reduced RyR1 content in the sarcoplasmic reticulum membrane would cause a decrease of calcium release during excitation contraction coupling, leading to weak muscles. These results have important implications namely, (i) the development of a single therapeutic strategy to improve muscle function in patients bearing RYR1 mutation is not plausible and (ii) the type of treatment will depend on the type(s) of mutations.
The pathological mechanism leading to reduced RyR1 content in patient’s muscle is unknown. Our working hypothesis is that the presence of recessive RYR1 mutations (compound heterozygous with a mis-sense+ frameshift/nonsense mutation and homozygous mis-sense) activates an epigenetic loop involving chromatin modifying enzymes, leading to reduced expression of RyR1. Thus, pharmacologically targeting chromatin modifying enzymes, including histone de-acetylases (HDACs) and DNA methyl transferase (DNMTs) may represent a valid therapeutic approach. In order to investigate this in a pre-clinical setting, we have created a mouse model knocked in for compound heterozygous Ryr1 mutations identified in severely affected child, namely the DKI mouse carrying a frameshift mutation in Ex36+ a mis-sense mutation in Ex91.
In this project we will address the following specific aims: 1) establish whether treatment of the DKI mice with HDAC/DNMT inhibitors (the drugs alone or in combination) results in improved muscle function; 2) elucidate the molecular and biochemical mechanisms leading to the improved muscle function brought about by HDAC/DNMT inhibitor treatment.
The results of this study will have important implications especially since they will promote the development of pharmacological therapies to improve muscle function and thus the quality of life of patients with disorders leading to a decrease of RyR1 expression in their skeletal muscles.
Lay summary
Questo progetto rappresenta la continuazione del progetto condotto nel 2019-2020, in cui sono stati ricercati i meccanismi che conducono ad una ridotta espressione della proteina RyR1 in pazienti con malattie muscolari congenite, portatori di mutazioni recessive nel gene RYR1.
Utilizzando il modello murino Ryr1 DKI che abbiamo creato nel nostro laboratorio, ci proponiamo ora di saggiare se alcune molecole in grado di inibire i meccanismi intracellulari che abbiamo identificato, sono in grado di ristabilire la funzione muscolare nei modelli murini. I risultati di questo studio sono importanti per sviluppare terapie farmacologiche per pazienti che soffrono di miopatie congenite quali la miopatia multiminicore, la miopatia centronucleare e la miopatia da disproporzione congenita del tipo di fibra.
Progetti
- Nuovi progetti di ricerca dal 2024
- L'importanza della ricerca
- Progetti finanziati
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Opuscolo progetti
- SEAL Therapeutics AG
- Meeting e workshop
- Partecipazione ad altre organizzazioni
- Registri dei pazienti
- La rete Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch